In Europe, meanwhile, the focus will be on any disruption or delays to the approval process as the European Medicines Agency prepares to relocate from London to Amsterdam as a result of Britain’s decision to leave the EU.
Related Articles
Drug UPDATES
Information on New Approvals and Medication Safety
Stronger Together: The Future of Physician Unions
If you ever want to be depressed, turn to the internet. This might strike some of you as a truism. Certainly, between the pandemic and the war in Ukraine, it is difficult to open your browser without being smacked in the face by a dismally depressing piece of news. In this particular case, however, I’m…
FDA Rheumatology Update: New Drug Approvals, Plus Expanded Drug Indications & Safety Concerns
Last year, the FDA was busy with new biologic and other drug approvals, new and expanded drug indications, and important safety updates relevant to rheumatology…
FDA Update: New Drug Approvals, New & Expanded Indications, & More
ATLANTA—New drug approvals, new and expanded drug indications, and important safety and other updates relevant for rheumatologists were presented by three physicians from the U.S. Food & Drug Administration (FDA) on Nov. 11 at the 2019 ACR/ARP Annual Meeting. New JAK Inhibitor Approved for RA On Aug. 16, 2019, the FDA approved upadacitinib (Rinvoq), an…